Novo Nordisk's CEO has announced plans to seek regulatory approval in China for an oral version of Wegovy (semaglutide), targeting one of the world's largest untapped obesity markets. China's obesity epidemic is well-documented, with hundreds of millions of potential patients, and an oral formulation could dramatically lower the barrier to adoption versus injectable versions that currently dominate the GLP-1 landscape.

The key question is whether Chinese regulators will move quickly, and whether Novo can price Wegovy competitively against domestic GLP-1 rivals already developing similar molecules at lower cost. Investors should watch for formal NMPA submission timelines, any pricing guidance for China, and progress from domestic Chinese pharma competitors — all of which will shape how material this opportunity actually becomes for NVO's revenue outlook.